Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Friday, February 13, 2009

1983 review paper: The Diagnostic Potential of Breath Analysis

Approximately 200 compounds have been detected in human breath, some of which have been correlated to various diseases. With the advent of new technology that may permit the rapid analysis of breath, further progress can be anticipated in the use of breath metabolites for the diagnosis of disease, including neonatal screening, toxicology, and metabolic disease.
This 1983 paper is of interest mainly because of it's lists (which may or may not be outdated), demonstrating the potential of detecting compounds through breath. Particularly from alveolar breath, which is breath from the lungs that is being exhaled from the system. Such as the way breathalyzers detect alcohol. The lists demonstrate the authors thoughts on potential compounds that could be detected at the time. Trimethylamine gets a brief mention.

Breath analyzers certainly seem a potentially useful tool in diagnosing systemic body odor and both types of halitosis. Perhaps someday there may even be portable breathalyzers for the detection of compounds such as trimethylamine, so that sufferers can monitor their trimethylamine levels. Or trimethylamine test papers so that urine can be easily tested. Perhaps this sort of technology is already out there but they don't realise there is a market.

The metabolites excreted in the breath may be divided into five groups:

1. Lipid degradation products: Numerous diseases will affect the concentration of total serum fatty acid or the fatty acid chromatographic pattern in the breath. Breath acetone has already been shown to be useful in monitoring diabetes(13).
2. Aromatic compounds: Toluene and other alkylbenzenes, furan, naphthalene, and p-tolualdehyde have been detected in the breath (9-11). The origin of these compounds in the breath is generally not known.
3. Thio compounds: Methanethiol, ethanethiol, dimethylsulfides, and, in smaller concentrations, higher alkanethiol and alkylsulfides are present in human breath (9-11). Increased concentrations of specific thio-compounds have already been shown to have diagnostic significance in cirrhosis(14, 15) and ovulation (16).
4. Ammonia and amines: Ammonia would be expected to be increased in hepatic disease (although serum ammonia does not correlate well with hepatic coma) (17). Dimethylamine and triethylamine are increased in uremia (18).
5. Halogenated compounds: These are probably derived from inhaled, injected, or absorbed environmental pollutants and are of interest in industrial toxicology (8).


Post a Comment